- 88 Downloads
Tolterodine is a competitive muscarinic receptor antagonist that shows in vivo selectivity for the bladder over the salivary glands compared with oxybutinin.
Results of randomised double-blind placebo-controlled studies indicate that tolterodine 4 mg/day (administered as immediate-release tablets 2mg twice daily or extended-release capsules 4mg daily) is superior to placebo in improving micturition diary variables in patients with overactive bladder. Moreover, tolterodine 2mg twice daily is as effective as oxybutynin 5mg 3 times daily. Maximum treatment effects with both drugs occurred after 5 to 8 weeks of treatment and improvements were maintained during long term treatment for up to 24 months.
In a pooled analysis of four 12-week studies, equivalent and significant reductions in micturition frequency (−2.3 and −2.0 vs −1.4, p < 0.001) and the incidence of urge incontinence episodes (−1.6 and −1.8 vs −1.1, p < 0.05) were reported for tolterodine 2mg twice daily and oxybutynin 5mg 3 times daily compared with placebo. Functional bladder capacity was also significantly increased.
Improvements in patient perceptions of their urgency symptoms and of problems caused by their bladder condition were significantly greater during treatment with tolterodine than with placebo.
Tolterodine was generally well tolerated in clinical trials of up to 24 months’ duration. Dry mouth was the most frequent adverse event. The incidence (40 vs 78%, p < 0.001) and intensity of this event was lower with tolterodine 2mg twice daily than oxybutynin 5mg 3 times daily. Additionally, a 23% lower incidence of dry mouth was reported with once daily extended-release tolterodine capsules than with twice daily immediate-release tablets (p < 0.02). The incidence of adverse CNS events with tolterodine was low and similar to that of placebo. Tolterodine was well tolerated in elderly patients and no serious tolerability concerns were identified.
Conclusions: Tolterodine is the first antimuscarinic agent to be specifically developed for the treatment of overactive bladder. The functional selectivity of tolterodine for the bladder translates into good efficacy and tolerability in patients, including the elderly, with overactive bladder. Tolterodine is as effective as oxybutynin in improving micturition diary variables but is associated with a significantly lower incidence and intensity of dry mouth. This favourable tolerability profile, together with sustained clinical efficacy during long term treatment, places tolterodine as a valuable treatment for the symptoms of overactive bladder.
Tolterodine and its active 5-hydroxymethyl metabolite (5-HM) are potent and competitive muscarinic receptor antagonists and share a similar pharmacological profile. Neither compound showed specificity for any particular muscarinic receptor subtype in radioligand-binding studies.
Tolterodine and oxybutynin are equipotent muscarinic receptor antagonists in vitro. Carbachol-induced contractions of guinea-pig urinary bladder strips and nerve-mediated contractions of isolated human detrusor preparations were inhibited to a similar extent by tolterodine and oxybutynin.
Tolterodine and 5-HM show functional selectivity for the bladder over the salivary glands in vivo compared with oxybutinin. In the anaesthetised cat, intravenous tolterodine and 5-HM produced more effective inhibition of acetylcholine-induced bladder contraction than of electrically-evoked salivation. In contrast, oxybutynin showed the opposite selectivity profile.
In clinical studies involving healthy volunteers, tolterodine inhibited urodynamic bladder function, had a longer duration of effect on the bladder than on the salivary glands and a greater magnitude of effect on bladder function than on visual accommodation. The pharmacodynamic effects of tolterodine were not generally influenced by metabolic phenotype.
The pharmacokinetic properties of tolterodine are influenced by cytochrome P450 (CYP) 2D6 polymorphism. In individuals lacking this enzyme, described as poor metabolisers, the active metabolite 5-HM cannot be formed and pharmacological effects are mediated by tolterodine alone. In contrast, the pharmacologically active moiety is represented by the sum of unbound tolterodine and 5-HM in extensive metabolisers. Nevertheless, the same dosage can be used irrespective of CYP2D6 phenotype as exposure to pharmacologically active moiety is comparable for the two subgroups.
Tolterodine is rapidly absorbed after oral administration of the immediate-release tablet formulation, reaching peak serum levels (Cmax) within 1 to 2 hours (tmax) in healthy volunteers. The effective exposure to tolterodine is unaffected by the presence of food. Tolterodine is extensively bound to plasma proteins (3.7% remaining unbound), whereas 36% of 5-HM exists as free drug.
Pharmacokinetic equivalence was demonstrated between a once daily extended-release capsule formulation of tolterodine 4mg and (immediate-release) tolterodine tablets 2mg twice daily. However, serum drug levels fluctuated less with the former preparation as evinced by median Cmax values of the active moiety that were around 75% of that observed with the twice-daily tablet formulation whereas minimum serum concentrations were 1.5-fold higher. The extended-release capsule formulation shows no evidence of ‘dose-dumping’ when administered with meals.
Tolterodine undergoes extensive first-pass hepatic metabolism, predominantly via CYP2D6-mediated oxidation and CYP 3A4-mediated N-dealkylation. With the exception of 5-HM, metabolites of tolterodine are not considered to contribute to the therapeutic effect.
Tolterodine (immediate-release tablets) has a mean systemic clearance of 44 L/h and an elimination half-life of 1.9 to 3.6 hours in extensive metabolisers. In poor metabolisers, tolterodine clearance is 5-fold lower (mean 9.0 L/h) and the elimination half-life is correspondingly longer (7.5 to 11 hours). In both poor and extensive metabolisers, the tmax and elimination half-lives of tolterodine and 5-HM were longer after administration of extended-release capsules than immediate-release tablets, consistent with a slower release of drug from the former preparation.
The clearance of tolterodine is considerably lower in patients with hepatic cirrhosis or renal impairment [creatinine clearance 10 to 30 ml/min (0.6 to 1.8 L/h)] than in healthy volunteers. In poor metabolisers, the CYP3A4 inhibitor ketoconazole appeared to reduce the clearance of tolterodine. No clinically significant drug-drug interactions were evident in patients receiving treatment with tolterodine and fluoxetine, warfarin or ethinylestradiol/levonorgestrel. Tolterodine is not expected to alter the metabolism of substrates of CYP 2D6, 2C19, 3A4 or 1A2.
In patients with overactive bladder, 2 weeks’ treatment with immediate-release tolterodine tablets 0.5 to 4mg twice daily produced significant dose-related improvements in bladder function as evinced by increases in the volume at first contraction and maximum cystometric capacity compared with baseline.
Tolterodine immediate-release tablets 1 and 2mg twice daily improved micturition diary variables compared with baseline during 4 to 16 weeks’ treatment and consistently produced greater improvements than placebo in patients with overactive bladder. In a pooled analysis of 12-week twice daily dosage studies (n = 1120 patients), tolterodine 1 and 2mg significantly reduced micturition frequency and the incidence of urge incontinence episodes compared with placebo. Furthermore, the increase in volume voided/micturition was also significantly greater for both dosages of tolterodine than with placebo. Tolterodine 2mg twice daily was also effective in improving micturition diary variables in elderly patients (aged ≥65 years) with symptoms of overactive bladder.
In comparative studies, the efficacy of tolterodine immediate-release tablets 2mg twice daily in improving micturition diary variables was comparable with that of oxybutynin 5mg twice or 3 times daily. Statistical equivalence for reductions in micturition frequency and the incidence of urge incontinence episodes was demonstrated between tolterodine and oxybutynin after 12 weeks’ treatment. For both drugs, maximum efficacy was reached after 5 to 8 weeks of treatment.
When administered at a total daily dosage of 4 mg/day for 12 weeks, the once daily extended-release capsule formulation of tolterodine was significantly more effective than twice daily immediate-release tablets in reducing the incidence of urge incontinence episodes. Respective median reductions of 71 and 60% were reported, versus 33% in the placebo group. Compared with placebo, the active treatments had similar efficacy in significantly improving micturition frequency and the mean volume voided/micturition.
Patient perceptions of their urgency symptoms were also improved by tolterodine, administered as twice daily immediate-release tablets or once daily extended-release capsules. Significant improvements in several domains of King’s Health Questionnaire quality of life instrument were reported after 10 weeks’ treatment with tolterodine immediate-release tablets 2mg twice daily. Effects were similar to those of oxybutynin 5mg twice daily.
The clinical efficacy of tolterodine immediate-release tablets 2mg twice daily in improving micturition diary variables was maintained during long term treatment of up to 24 months’ duration.
Reports of a single 16-week noncomparative study indicate that tolterodine immediate-release tablets 2mg twice daily is also effective in treating urinary symptoms in women with mixed incontinence (urge incontinence predominating).
Tolterodine at dosages up to 2mg twice daily (immediate-release tablets) or 4mg once daily (extended-release capsules) was well tolerated during clinical trials of up to 24 months’ duration in patients, including the elderly, with overactive bladder. There was no difference in the nature of adverse events occurring in poor or extensive metabolisers of tolterodine.
The percentage of tolterodine-treated patients experiencing adverse events was comparable with that in placebo recipients. The most frequently reported adverse events were autonomic nervous system, gastrointestinal and general body disorders. Adverse CNS events were uncommon during placebo-controlled studies and occurred in a similar percentage of patients receiving tolterodine and placebo. No clinically significant changes in blood pressure, ECG or laboratory variables were reported during treatment with tolterodine immediate-release tablets 2mg twice daily for up to 12 months.
Dry mouth was the most commonly reported adverse event thought to be related to tolterodine treatment. The incidence of dry mouth was significantly lower in patients receiving tolterodine 1 or 2mg twice daily or placebo (24, 40 and 16%, respectively) than among oxybutynin 5mg 3 times daily recipients (78%). Additionally, the intensity of dry mouth was lower with tolterodine 1 or 2mg twice daily or placebo than with oxybutynin; severe dry mouth was reported by 2, 4, 3 and 29% of patients, respectively. Interestingly, once daily treatment with the extended-release capsule formulation of tolterodine was associated with a significant 23% lower incidence of dry mouth than with twice daily tablets (at the same total daily dosage of 4 mg/day).
Tolterodine immediate-release tablets 2mg twice daily was well tolerated during long term treatment in >1500 patients. Generally, the incidence of adverse events after 9 or 12 months’ treatment was similar to that reported in 12-week studies. Dry mouth occurred in 28 and 41% of patients, respectively, and approximately two-thirds of these episodes were mild in intensity. 70 and 62% of patients completed the 9- and 12-month studies, respectively.
Dosage and Administration
The recommended oral dosage of tolterodine immediate-release tablets in adult patients with overactive bladder is 2mg twice daily, which may be lowered to 1mg twice daily based on individual response and tolerability. Tolterodine may be administered without respect to mealtimes and no dosage adjustment is needed in the elderly. An extended-release capsule formulation of tolterodine (4mg once daily) has recently been approved by regulatory authorities.
Patients with reduced renal or hepatic function or those receiving concomitant CYP3A4 inhibitors should receive dosages of tolterodine no greater than 2 mg/day. Caution should be used when administering tolterodine to patients with clinically significant bladder outflow obstruction or gastrointestinal obstructive disorders, or to those receiving treatment for narrow-angle glaucoma. Tolterodine is contraindicated in patients with urinary retention, gastric retention or uncontrolled narrow-angle glaucoma, and should be discontinued during nursing. Tolterodine should only be used during pregnancy if the potential benefit for the mother justifies the potential risk to the fetus.
KeywordsOveractive Bladder Oxybutynin Urge Incontinence Tolterodine Antimuscarinic Agent
- 5.Fantl JA, Newman DK, Colling J, et al. Urinary incontinence in adults: acute and chromic management. Clinical practice guideline, No. 2, 1996 Update. Rockville (MD): US Department of Human Services. Public Health Service, Agency for Health Care Policy and Research. March 1996. AHCPR Publication No. 96-0682Google Scholar
- 14.Nilvebrant L, Sundquist S, Gillberg P-G. Tolterodine is not subtype (ml-m5) selective but exhibits functional bladder selectivity in vivo [abstract no. 34]. Neurourol Urodyn 1996; 15(4): 310–1Google Scholar
- 15.Naerger H, Ery CH, Nilvebrant L. Effect of tolterodine on electrically induced contactions of isolated human detrusor muscle from stable and unstable bladders [abstract]. Neurourol Urodyn 1995; 14 (Pt 5): 524–6Google Scholar
- 19.Chancellor MB. Tolterodine: selectivity for the bladder over effects on visual accommodation [abstract no. 1019]. J Urol 2000 Apr; 163 Suppl.: 229Google Scholar
- 22.Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride and oxybutynin on the central nervous system. J Clin Pharmacol. In pressGoogle Scholar
- 24.Pharmacia & Upjohn. Detrol tolterodine tartrate tablets prescribing information. Kalamazoo (MI): Pharmacia & Upjohn Co., 2001 JanGoogle Scholar
- 29.Nilvebrant L, Påhlman I, d’Argy R. Tissue distribution of tolterodine and its metabolites: low penetration into the central nervous system. XV Meeting of the European Association of Urology, 2000 Apr 12–15, BrusselsGoogle Scholar
- 33.Pharmacia & Upjohn. Detrol LA tolterodine tartrate extended release capsules prescribing information. Kalamazoo (MI): Pharmacia & Upjohn Company, 2000 DecGoogle Scholar
- 38.Abrams P, Jackson S, Mattiasson A, et al. A randomised, double-blind, placebo controlled, dose ranging study of the safety and efficacy of tolterodine in patients with hyperreflexia [abstract]. 26th Annual Meeting of the International Continence Society; 1996 Aug 27–30; Athens, 259Google Scholar
- 43.Jacquetin B, Wyndaele J-J. Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder. Eur J Obstet Gynecol Reprod Biol. In pressGoogle Scholar
- 44.Malone-Lee JG, Walsh JB, Maugourd M-F, et al. Tolterodine: a safe and effective treatment for elderly patients with overactive bladder. J Am Geriatr Soc. In pressGoogle Scholar
- 46.Malone-Lee JG, Shaffu B, Anand C, et al. Tolterodine: superior tolerability and comparable efficacy with oxybutynin in older individuals with overactive bladder. J Urol. In pressGoogle Scholar
- 49.Van Kerrebroeck PEVA, Serment G, Dreher E. Clinical efficacy and safety of tolterodine compared to oxybutynin in patients with overactive bladder [abstract no. 91]. Neurourol Urodyn 1997; 16(5): 478–9Google Scholar
- 52.Rabin JM. Tolterodine is rapidly effective in women with mixed incontinence [abstract]. Int J Gynaecol Obstet. In pressGoogle Scholar
- 53.Payne C, Rabin JM. Tolterodine is rapidly effective in women with mixed incontinence [abstract]. Proceedings of the 30th Annual Meeting of the International Continence Society; 2000 Aug 28–31; Tampere, FinlandGoogle Scholar
- 54.Van Kerrebroeck PEVA. Significant decreases in perception of urgency and urge incontinence episodes with once-daily tolterodine treatment in patients with overactive bladder [poster]. Proceedings of the 30th Annual Meeting of the International Continence Society; 2000 Aug 28–31; Tampere, FinlandGoogle Scholar
- 56.Kelleher C. Health-related quality of life of female patients receiving once-daily tolterodine treatment for overactive bladder [abstract and poster]. Int Urogynecol J Pelvic Floor Dysfunct. In pressGoogle Scholar
- 57.Abrains P, Malone-Lee J, Jacquetin B, et al. Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine. Drugs Aging. In pressGoogle Scholar
- 58.Appell RA, Abrams P, Drutz HP, et al. Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J Urol. In pressGoogle Scholar
- 62.Drutz HP. Tolterodine is effective amd well tolerated during long-term use in patients with overactive bladder [abstract]. Int J Gynaecol Obstet. In pressGoogle Scholar
- 64.Pharmacia & Upjohn. Detrusitol. In: Walker G, compiler. ABPI Compendium of data sheets and summary of product characteristics 1999–2000. London: Datapharm Publications Ltd, 2000: 1188–9Google Scholar
- 66.Abrains P, Wein AJ, editors. The overactive bladder: a widespread and treatable condition. Stockholm: Erik Sparre Medical AB, 1998Google Scholar
- 67.Wein AJ, Rovner ES. The overactive bladder: an overview for primary care health providers. Int J Fertil 1999; 44: 56–66Google Scholar
- 70.Kobelt-Nguyen G, Johannesson M, Marrasson A, et al. Correlation between symptoms of urge incontinence and scores of a generic quality of life instrument (SE36) and health status measurements (EUROQOL) and between changes in symptoms and QoL scores [abstract no. 195]. Annual Meeting of the International Continence Society; 1997 Sep 23–26; YokohamaGoogle Scholar
- 71.Johannesson M, O’Conor RM, Kobelt-Nguyen G, et al. Willingness to pay for reduced incontinence symptoms. Br J Urol 1997; 88: 557–62Google Scholar
- 73.AHCPR Urinary Incontinence in Adults Guideline Update Panel. Managing acute and chronic urinary incontinence. Am Fam Physician 1996 Oct; 54: 1661–72Google Scholar
- 74.National Institutes of Health Consensus Development Conference. Urinary incontinence in adults. J Am Geriatr Soc 1989; 261: 2685–90Google Scholar
- 75.Thuroff JW, Bunke B, Ebner A, et al. Randomized, doubleblind, multicenter tirai on treatment of frequency, urgency and incontinence related to detrusor hyperactivity; oxybutynin versus propantheline versus placebo. J Urol 1991; 145: 531–9Google Scholar
- 80.Ditropan XL needs longer trial to support superiority claim for dry mouth. Pharm Approv Monthly 1999 Apr; 161 Suppl.: 26–30Google Scholar
- 84.Oxybutynin hydrochloride. British National Formulary 40. London: British Medical Association, Royal Pharmaceutical Society of Great Britain, 2000 Sep: 382–3Google Scholar